Search our Database of Scientific Publications and Authors

I’m looking for a

    3285 results match your criteria Plaque Psoriasis

    1 OF 66

    Wirksamkeit und Sicherheit von Fumarsäureestern in Kombination mit Phototherapie bei Patienten mit moderater bis schwerer Plaque-Psoriasis (FAST).
    J Dtsch Dermatol Ges 2017 Feb;15(2):180-188
    SCIderm GmbH, Hamburg.
    Hintergrund: Die Behandlung von Psoriasis-Patienten mit einer Kombination aus Fumarsäureestern (FSE, Fumaderm(®) ) und Phototherapie (UV) ist verbreitet, wurde aber im Rahmen von Studien wenig untersucht. Bisher liegen lediglich Daten aus einer kleinen Pilotstudie vor. Intention dieser Studie war, eine FSE/UV-Kombinationsbehandlung an einem größeren Patientenkollektiv mit mittelschwerer bis schwerer Psoriasis zu untersuchen. Read More

    Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST).
    J Dtsch Dermatol Ges 2017 Feb;15(2):180-186
    SCIderm GmbH, Hamburg, Germany.
    Background: While treatment of patients with moderate-to-severe psoriasis using a combination of fumaric acid esters (FAE, Fumaderm(®) ) and phototherapy (UV) is common practice, there have been hardly any studies investigating this regimen. Available information is limited to data from a small pilot study. The objective of the present study was to evaluate FAE/UV combination therapy in a larger patient cohort with moderate-to-severe psoriasis. Read More

    Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Drugs 2017 Feb 18. Epub 2017 Feb 18.
    Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
    Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast. Read More

    Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
    Clin Drug Investig 2017 Feb 14. Epub 2017 Feb 14.
    Medical Research Group of Egypt, Cairo, Egypt.
    Background: Psoriasis is an inflammatory skin disease that affects 2-3% of the worldwide population. The interleukin-17 cytokine family has been proven to play a central role in the pathogenesis of psoriasis. Brodalumab is a novel biologic agent that targets interleukin-17 molecules and their receptors. Read More

    Open-label study of etanercept treatment in patients with moderate to severe plaque psoriasis who lost a satisfactory response to adalimumab.
    Br J Dermatol 2017 Feb 14. Epub 2017 Feb 14.
    Probity Medical Research, Ontario, Canada.
    Background: Some plaque psoriasis patients experience secondary failure of tumour necrosis factor inhibitor therapy.

    Objectives: To evaluate efficacy, safety, and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure.

    Methods: This phase 4, open-label, single-arm, estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static physician global assessment (sPGA) score 0/1 (clear/almost clear). Read More

    Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia.
    Int J Dermatol 2017 Feb 14. Epub 2017 Feb 14.
    Department of Dermatology Hospital Sultanah Aminah, Johor Bahru, Malaysia.
    Background: Limited information exists regarding juvenile generalized pustular psoriasis (GPP). We aim to determine the clinical profile and outcome of Malaysians with juvenile GPP.

    Methods: Review of hospital case notes on patients with juvenile GPP. Read More

    Fatigue in psoriasis - a controlled study.
    Br J Dermatol 2017 Feb 9. Epub 2017 Feb 9.
    Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.
    Background: Fatigue is associated with various chronic inflammatory diseases, but few studies have focused on its occurrence in psoriasis.

    Objectives: To describe fatigue prevalence and degree among patients with chronic plaque psoriasis compared with age- and gender-matched healthy subjects, and to examine how fatigue is influenced by essential clinical and demographic factors.

    Methods: In 84 patients and 84 healthy subjects, fatigue severity was assessed using three different generic fatigue instruments: the fatigue Visual Analogue Scale (fVAS), the Fatigue Severity Scale (FSS), and the Short Form 36 (SF-36) vitality scale. Read More

    Legionella pneumophila pneumonia possibly due to ustekinumab therapy in a patient with Crohn's disease.
    Am J Health Syst Pharm 2017 Feb;74(4):209-212
    Internal Medicine Division, Hospital de Sagunto, Sagunto, Spain.
    Purpose: A case report of Legionella pneumophila pneumonia associated with off-label use of ustekinumab in a patient with Crohn's disease (CD) is presented.

    Summary: A 57-year-old man with longstanding CD was hospitalized with a four-day history of fever (38.5 °C), dyspnea, left pleuritic pain, and weight loss (more than 6 kg) about six weeks after beginning treatment with ustekinumab, a human monoclonal antibody approved in the United States for two indications (plaque psoriasis and psoriatic arthritis) and currently under investigation as a potential treatment for CD and other inflammatory disorders. Read More

    Psoriasis in systemic lupus erythematosus: a single-center experience.
    Clin Rheumatol 2017 Feb 6. Epub 2017 Feb 6.
    Centre for Prognosis Studies in the Rheumatic Diseases Toronto Western Hospital, University of Toronto Lupus Clinic, University Health Network, 399 Bathurst St. 1E-410B, Toronto, ON, M5T 2S8, Canada.
    The coexistence of psoriasis with systemic lupus erythematosus (SLE) has been reported in limited case series, raising hypotheses about shared pathogenetic mechanisms. Nevertheless, important differences regarding treatment do exist. The aim of the present study was to determine the prevalence and characteristics of psoriasis in a defined cohort of lupus patients. Read More

    Secukinumab in the treatment of psoriasis: an update.
    Immunotherapy 2017 Feb 6. Epub 2017 Feb 6.
    Department of Dermatology, Venereology & Allergology, Wroclaw Medical University, Chalubinskiego 1, 50-368 Wroclaw, Poland.
    Biological drugs are pharmaceuticals manufactured using biotechnology methods that may target specific cytokines, cytokine receptors or surface molecules, and modulate the immunological response of the organism. Psoriasis is a common cutaneous disease in which biological drugs have been evaluated and widely accepted in clinical practice. Secukinumab is a monoclonal antibody targeting IL-17A which has been extensively researched in clinical trials and registered in treating moderate to severe plaque psoriasis. Read More

    Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.
    Dermatology 2017 Feb 3. Epub 2017 Feb 3.
    Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
    Background/aims: Psoriasis as a dermatological disorder has complex effects on mental health and the psychological status of the patient. Many authors proposed that assessing how psoriasis affects a patient's life is better than a body surface area measurement for delineating psoriasis severity. Alexithymia is a personality dimension characterized by difficulty identifying feelings, difficulty describing feelings, and externally oriented thinking observed in many clinical conditions, especially in psychosomatic disorders. Read More

    Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis.
    J Dermatol 2017 Feb 2. Epub 2017 Feb 2.
    Krankenanstalt Rudolfstiftung, Wien, Austria.
    Ustekinumab, a monoclonal antibody that binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, is approved in the USA and Europe for moderate to severe plaque psoriasis. There are concerns that biologic treatments like ustekinumab may lead to an increased rate of infections. We report a 77-year-old woman who developed varicella zoster virus meningitis 8 weeks after initiation of ustekinumab therapy because of plaque psoriasis. Read More

    Development and Psychometric Evaluation of the Self-Assessment of Psoriasis Symptoms (SAPS) - Clinical Trial and the SAPS - Real World Patient-Reported Outcomes.
    J Dermatolog Treat 2017 Feb 2:1-41. Epub 2017 Feb 2.
    b Adelphi Values USA , Boston , Massachusetts , USA.
    Objective: The Self-Assessment of Psoriasis Symptoms- Clinical Trials (SAPS-CT), and SAPS- Real World (SAPS-RW) were simultaneously created to assess the experience of plaque psoriasis in two unique contexts.

    Methods: Qualitative and quantitative research was conducted in four phases: concept elicitation; questionnaire construction; content evaluation; and psychometric evaluation.

    Results: Following concept elicitation, 18 concepts were selected to inform questionnaire construction of the SAPS-CT and -RW. Read More

    Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study.
    J Eur Acad Dermatol Venereol 2017 Feb 1. Epub 2017 Feb 1.
    Department of Dermatology, University of Verona.
    Introduction: Despite the large routine use of biologic drugs in psoriasis treatment, the majority of studies do not take into consideration dose-adjustment practice in "real life" dermatological setting. In routine clinical practice the disease management may include a large number of conditions requiring non-standard dosage regimens, including dose-escalation, dose-reduction and/or off-label treatment interruption.

    Objective: The ONDA (Outcome of non-standard dosing regimen in Psoriasis and Psoriatic Arthritis) study aim was to retrospectively analyse dose-adjustment strategies among biologic therapies for psoriasis in dermatological practice during a 3-year period. Read More

    Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Am J Clin Dermatol 2017 Feb;18(1):147-158
    Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
    Ixekizumab (Taltz(®)) is a subcutaneously administered, humanized anti-interleukin-17A monoclonal antibody indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (USA and EU) or phototherapy (USA). In the phase 3 UNCOVER trials in this patient population, ixekizumab was superior to placebo or etanercept in terms of the proportion of patients achieving a ≥75% reduction from baseline in the Psoriasis Area and Severity Index and in those achieving a static Physician Global Assessment score of 0 or 1, after 12 weeks of induction treatment. Clinical responses to ixekizumab were seen as early as week 1. Read More

    Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.
    Mod Pathol 2017 Jan 27. Epub 2017 Jan 27.
    Department of Dermatology and Pathology, Stanford University, Stanford, CA, USA.
    Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma is a rare and poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the latest 2016 World Health Organization Classification of Cutaneous lymphomas. We sought to better characterize and provide diagnostic and therapeutic guidance of this rare cutaneous lymphoma. Thirty-four patients with a median age of 77 years (range 19-89 years) presented primarily with extensive annular necrotic plaques or tumor lesions with frequent mucous membrane involvement. Read More

    Socioeconomic Inequalities and Severity of Plaque Psoriasis at a First Consultation in Dermatology Centers.
    Acta Derm Venereol 2017 Jan 27. Epub 2017 Jan 27.
    Department of Dermatology, CH Victor Dupouy, FR-95100 Argenteuil, France.
    Psoriasis has major physical, psychological, and social impacts: its management should not be restricted by individual financial considerations in Western countries as these have well-structured health systems and social/insurance coverage. We investigated if the socioeconomic characteristics of patients were associated with severity of psoriasis and access to healthcare. In a cross-sectional study, we included 903 patients with psoriasis that were consulting for the first time. Read More

    A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
    Skin Therapy Lett 2017 Jan;22(1):1-6
    Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
    Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia that affects 2-3% of the population. Interleukin (IL)-17 signaling has a central role in its pathogenesis. Brodalumab is a monoclonal antibody that neutralizes IL-17 receptor type A. Read More

    In a Rare Head-to-Head Matchup, New Psoriasis Drug Seems a Winner.
    Manag Care 2016 Jul;25(7):33-34
    Taltz is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is delivered as a subcutaneous injection. The agent comes as either a pre-filled syringe or an autoinjector and can be self-injected after proper training and with physician supervision. Read More

    Siramesine causes preferential apoptosis of mast cells in skin biopsies from psoriatic lesions.
    Br J Dermatol 2017 Jan 24. Epub 2017 Jan 24.
    Department of Medical Sciences, Dermatology and Venereology, Uppsala University, Uppsala, Sweden.
    Background: Skin mast cells are implicated as detrimental effector cells in various inflammatory skin diseases such as contact eczema, atopic dermatitis and psoriasis. Selective reduction of cutaneous mast cells, e.g. Read More

    Efficacy and relapse-suppression of severe plaque psoriasis by oxymatrine: Results from a single blinded randomized controlled clinical trial.
    Br J Dermatol 2017 Jan 23. Epub 2017 Jan 23.
    Ningxia Medical University.
    Background: Current drugs in psoriasis treatment are associated with drawbacks such as rapid recrudescence, high costs and unwanted side effects. Oxymatrine has a long clinical use in the treatment of hepatitis and cancer in China.

    Objective: To explore the efficacy and safety of oxymatrine injection in patients with severe plaque psoriasis. Read More

    Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
    J Eur Acad Dermatol Venereol 2017 Jan 23. Epub 2017 Jan 23.
    Novartis Pharma AG, Basel, Switzerland.
    Background: User satisfaction is an important factor associated with treatment adherence in chronic diseases including moderate-to-severe psoriasis.

    Objective: To evaluate the efficacy, safety and patient acceptability of 300 and 150 mg secukinumab - a fully human anti-interleukin-17A monoclonal antibody that has demonstrated efficacy in the treatment of patients with moderate-to-severe plaque psoriasis - self-administered by autoinjection.

    Methods: Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg or placebo self-administered by autoinjection at baseline, Weeks 1, 2 and 3 and then every 4 weeks from Week 4 to Week 48. Read More

    Psoriasis and palmoplantar pustulosis: an endless debate?
    J Eur Acad Dermatol Venereol 2017 Jan 20. Epub 2017 Jan 20.
    Dermatology Unit, Galliera Hospital, Genoa, Italy.
    Since 2007, palmoplantar pustulosis (PPP) has been classified as a separate entity and not a clinical variant of psoriasis despite the presence of certain phenotypes common in both diseases.(1) We read with interest the review by Misiak-Galazka et al., and we found that even after the extensive work (inclusion of 65 articles), some relevant data are missing. Read More

    Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials.
    J Eur Acad Dermatol Venereol 2017 Jan 20. Epub 2017 Jan 20.
    Second Departments of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
    Background: The interleukin-17 (IL-17) cytokine pathway plays a key role in the development of psoriasis. Antibodies targeting IL-17 or blocking its receptor may be a new therapeutic approach for psoriasis. To assist treatment selection in daily practice, it is essential to understand the benefit and risk profile of IL-17 antagonists. Read More

    A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
    J Eur Acad Dermatol Venereol 2017 Jan 20. Epub 2017 Jan 20.
    Department of Dermato-Venerology, Bispebjerg University Hospital, Copenhagen, Denmark.
    Background: Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases. AVX001, a cPLA2α inhibitor, was investigated in a randomized, double-blind, placebo-controlled, split-design, first-in-man study in patients with mild to moderate psoriasis.

    Objectives: The primary objective was to evaluate cutaneous safety and tolerability of AVX001 in doses from 0. Read More

    The Prevalence of Nonalcoholic Fatty Liver Disease and Related Metabolic Comorbidities Was Associated with Age at Onset of Moderate to Severe Plaque Psoriasis: A Cross-Sectional Study.
    PLoS One 2017 18;12(1):e0169952. Epub 2017 Jan 18.
    Department of Dermatology, Shanghai Dermatology Hospital, Shanghai, China.
    Nonalcoholic fatty liver disease (NAFLD) has been found to be highly prevalent in psoriatic patients. Adult onset psoriasis could be divided into either early or late onset psoriasis. The associations between NAFLD and related metabolic comorbidities and age at onset of psoriasis have not yet been investigated. Read More

    [Mexican treatment goals for plaque psoriasis].
    Rev Med Inst Mex Seguro Soc 2017 Jan-Feb;55(1):90-97
    Servicio de Dermatología, Hospital Regional Lic. Adolfo López Mateos, ISSSTE, Ciudad de México, México.
    Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease. The European group met to develop the definitions of severity of psoriasis, treatment goals for moderate to severe disease, and optimization options and / or therapeutic transition than a paper published in 2011 was obtained. Read More

    Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Am J Clin Dermatol 2017 Jan 10. Epub 2017 Jan 10.
    Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    Background: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A.

    Objective: Our aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using a post-hoc analysis in two phase III studies.

    Methods: For the subanalyses in two phase III trials (UNCOVER-2 and -3), non-response was defined by either failure to have a static physician global assessment (sPGA) of 0/1 in UNCOVER-2 or failure to have at least 75% improvement in psoriasis area and severity index (PASI 75) in UNCOVER-3 at Week 12 of each study. Read More

    Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
    Expert Opin Biol Ther 2017 Mar 25;17(3):395-402. Epub 2017 Jan 25.
    c Department of Medical affairs , Branded Formulations India , Biocon , Bengaluru , India.
    Introduction: Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Read More

    Xenotransplantation Model of Psoriasis.
    Methods Mol Biol 2017 ;1559:83-90
    Department of Dermatology, University Hospital CHUV, Avenue de Beaumont 29, 1011, Lausanne, Switzerland.
    Psoriasis is a chronic autoimmune skin disease affecting approximately 2 % of the population with a major psychosocial and socioeconomic impact. A causal therapy leading to permanent cure is not available, and current treatments only lead to limited amelioration, and therefore new therapeutic targets need to be identified. Recent works demonstrated a predominant role of TH17 cells in the pathogenesis of psoriasis; yet the underlying molecular mechanisms driving the development of the disease are still largely elusive. Read More

    Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner.
    Mediators Inflamm 2016 12;2016:6756138. Epub 2016 Dec 12.
    Department of Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, 1158 MERB, 3500 N. Broad Street, Philadelphia, PA 19140, USA.
    Generalized pustular psoriasis (GPP) is a severe form of psoriasis that can be caused by missense mutations in the interleukin-36 (IL-36) receptor antagonist. In addition to neutrophil rich skin inflammation, GPP patients typically also experience anorexia, fever, malaise, and pain. The imiquimod-induced skin inflammation mouse model has rapidly become a popular way to study plaque psoriasis, which typically does not involve symptoms of systemic disease. Read More

    IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.
    J Allergy Clin Immunol 2016 Dec 31. Epub 2016 Dec 31.
    Department of Dermatology, University of Michigan, Ann Arbor, Mich.
    Background: Generalized pustular psoriasis (GPP) is a rare, debilitating, and often life-threatening inflammatory disease characterized by episodic infiltration of neutrophils into the skin, pustule development, and systemic inflammation, which can manifest in the presence or absence of chronic plaque psoriasis (PV). Current treatments are unsatisfactory and warrant a better understanding of GPP pathogenesis.

    Objective: We sought to understand better the disease mechanism of GPP to allow improved targeted therapies. Read More

    The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    J Dermatolog Treat 2017 Jan 18:1-7. Epub 2017 Jan 18.
    b UCSF Department of Dermatology , San Francisco , CA , USA.
    Background: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. Read More

    Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity.
    Mediators Inflamm 2016 30;2016:4395276. Epub 2016 Nov 30.
    Laboratório de Imunomodulação e Novas Abordagens Terapêuticas (LINAT), Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino (NUPIT-SG), Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil.
    Psoriasis is a chronic and recurrent dermatitis, mediated by keratinocytes and T cells. Several proinflammatory cytokines contribute to formation and maintenance of psoriatic plaque. The Th1/Th17 pathways and some of IL-1 family members were involved in psoriasis pathogenesis and could contribute to disease activity. Read More

    Contribution of myeloperoxidase and inducible nitric oxide synthase to pathogenesis of psoriasis.
    Postepy Dermatol Alergol 2016 Dec 2;33(6):435-439. Epub 2016 Dec 2.
    Dermatology Department, Recep Tayyip Erdoğan University, Medical Faculty Hospital, Rize, Turkey.
    Introduction: Histological changes of psoriasis include invasion of neutrophils into the epidermis and formation of Munro abscesses in the epidermis. Neutrophils are the predominant white blood cells in circulation when stimulated; they discharge the abundant myeloperoxidase (MPO) enzyme that uses hydrogen peroxide to oxidize chloride for killing ingested bacteria.

    Aim: To investigate the contribution of neutrophils to the pathogenesis of psoriasis at the blood and tissue levels through inducible nitric oxide synthase (iNOS) and MPO. Read More

    An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet 2017 Feb 22;389(10068):528-537. Epub 2016 Dec 22.
    SCIderm GmbH Hamburg, Hamburg, Germany; Dermatologikum Hamburg, Hamburg, Germany. Electronic address:
    Background: Methotrexate is one of the most commonly used systemic drugs for the treatment of moderate to severe psoriasis; however, high-quality evidence for its use is sparse and limited to use of oral dosing. We aimed to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis.

    Methods: We did this prospective, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (METOP) at 16 sites in Germany, France, the Netherlands, and the UK. Read More

    Treatment Patterns and Outcomes among Adults Admitted to Hospital in the United Kingdom (UK) due to Plaque or Erythrodermic Psoriasis.
    Br J Dermatol 2016 Dec 23. Epub 2016 Dec 23.
    Newcastle Hospitals NHS Trust, Newcastle, UK.
    The National Institute for Health and Care Excellence (NICE) identified treatment of moderate-to-severe psoriasis as an area for research.(1-2) No recent studies have assessed treatment patterns and outcomes among patients hospitalised for psoriasis in the UK.(3-5) This study evaluated clinician- and patient-reported outcomes, treatment patterns, and hospital length of stay (LOS) in patients admitted to hospital for plaque or erythrodermic psoriasis, and enrolled 61 eligible patients across 9 UK hospital sites from 15 November 2013 to 2 June 2014. Read More

    Optimizing acitretin use in patients with plaque psoriasis.
    Dermatol Ther 2016 Dec 20. Epub 2016 Dec 20.
    Dermatology Department, University of Pisa, Via Roma 67, Pisa, 56126, Italy.
    Acitretin is one of the systemic agents used for the treatment of psoriasis. Because different acitretin dosages resulted therapeutically successful, there is no general agreement on the optimal dose regimen. To report acitretin efficacy and safety in a real-life setting, wherein patient-tailored dose regimen is usually prescribed, a retrospective analysis evaluating charts of all plaque-type psoriasis patients treated with acitretin from the clinic database was performed. Read More

    Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study.
    Br J Dermatol 2016 Dec 20. Epub 2016 Dec 20.
    Toulouse University and CHU Hôpital Larrey, Toulouse, France.
    Background: Single-centre studies show that alexithymia, defined as difficulty in recognizing and describing emotions, is more prevalent among psoriasis patients than in the general population. However, its prevalence and the consequences of the association between alexithymia and psoriasis are unclear.

    Objectives: The primary objective of this study was to determine the prevalence of alexithymia, as defined by a score ≥61 in the 20-item Toronto Alexithymia Scale (TAS-20), in a large sample of patients who had plaque psoriasis for ≤10 years and were eligible for phototherapy or systemic treatment. Read More

    Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.
    Clin Drug Investig 2016 Dec 19. Epub 2016 Dec 19.
    Centre de Pharmacologie Clinique Appliquée à la Dermatologie, Hôpital L'Archet 2, 06202, Nice Cedex 3, France.
    Background: Fixed combination calcipotriol as hydrate (Cal) 50 µg/g plus betamethasone as dipropionate (BD) 0.5 mg/g aerosol foam is an alcohol-free treatment for psoriasis. Betamethasone 17-valerate 2. Read More

    Biologics use in Indian psoriasis patients.
    Indian Dermatol Online J 2016 Nov-Dec;7(6):489-497
    Department of Dermatology, RNT Medical College, Udaipur, Rajasthan, India.
    The biologics currently in use for psoriasis in India are etanercept, infliximab and recently introduced itolizumab and secukinumab. Biosimilars, expected to play a significant role in psoriasis management in future, have also been available for the last few years. Patients with psoriasis may be considered eligible to receive treatment with any of the licensed biologic interventions when they fulfill the eligibility criteria. Read More

    Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring.
    Indian Dermatol Online J 2016 Nov-Dec;7(6):471-480
    Department of Dermatology, Venereology and Leprology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
    On the basis of current evidence derived from hospital-based studies, mostly from North India, the prevalence of psoriasis in adults varies from 0.44 to 2.8%, with a much lower prevalence in children. Read More

    Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients.
    Arch Dermatol Res 2017 Mar 17;309(2):79-86. Epub 2016 Dec 17.
    Department of Dermatology and Venereology, Medical University of Bialystok, Żurawia Str. 14, 15-540, Bialystok, Poland.
    Psoriasis is characterized by hyperproliferation, deregulated differentiation and impaired apoptosis of keratinocytes. Mechanisms of lipid profile disturbances and metabolic syndrome in the psoriatic patients are still not fully understood. Sphingolipids, namely ceramides (CER) and sphingosine-1-phosphate (S1P) are signal molecules which can regulate cell growth, apoptosis and immune reactions. Read More

    Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Pharmacogenomics 2017 Jan 15;18(2):157-164. Epub 2016 Dec 15.
    Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.
    Aim/Materials & methods: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We evaluated 121 polymorphisms to study a possible association between these SNPs and the response to ustekinumab (PASI75 at 4 months; n = 69).

    Results/conclusion: The adjusted results (false discovery rate) showed an association between five SNPs in TNFRSF1A, HTR2A, NFKBIA, ADAM33 and IL13 genes, and poor response to ustekinumab. Read More

    Inequalities in access to biological treatments for psoriasis: Results from the Italian Psocare Registry.
    Br J Dermatol 2016 Dec 14. Epub 2016 Dec 14.
    Department of Epidemiology, Lazio Region, Rome, Italy.
    Background: Limited evidence is available on the impact of socioeconomic factors in drug prescriptions for psoriasis.

    Objectives: To investigate factors influencing prescription of conventional versus biological treatment for psoriatic patients, based on the Psocare registry with a special focus on socioeconomic factors.

    Methods: This was a cross-sectional study evaluating the baseline data of patients included in the Italian Psocare Registry. Read More

    1 OF 66